Categories: News

Angion Announces Participation in Upcoming Investment Conference

UNIONDALE, N.Y., April 14, 2022 (GLOBE NEWSWIRE) — Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced participation in an upcoming investment conference.

Angion’s President and CEO, Dr. Jay Venkatesan, will participate in the Shareholder Equity Conference, held virtually. The presentation will be a fireside chat format and investors will have the opportunity to ask management questions during the live presentation. Details are as follows:

Shareholder Equity Conference (Virtual)

  • Thursday, April 21, 2022 at 11:30 AM ET

A webcast of the event will be accessible online by visiting the events and presentations page under the investors section of Angion’s website at https://ir.angion.com/events-presentations. The webcast will remain archived on Angion’s website for approximately 30 days.

About Angion Biomedica Corp.
Angion is committed to transforming the treatment paradigm for patients suffering from fibrotic diseases for which there are no approved medicines or where existing approved medicines have known limitations. Angion’s lead product candidate is ANG-3070, a highly-selective oral tyrosine kinase receptor inhibitor in development for the treatment of fibrotic kidney and lung diseases. Enrollment is ongoing in JUNIPER, a dose-finding Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases (NCT04939116). Additionally, Angion has preclinical programs focused on rho kinase 2 (ROCK2) inhibition and CYP11B2 (aldosterone synthase) inhibition. For more information, please visit www.angion.com

Contact
David D. Miller
Sr. Director of Communications & Investor Relations
investors@angion.com 

Staff

Recent Posts

Cellbxhealth PLC Announces Holding(s) in Company

GUILDFORD, SURREY / ACCESS Newswire / December 23, 2025 / Cellbxhealth PLC: TR-1: Standard form…

13 minutes ago

MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics

GENEVA, SWITZERLAND / ACCESS Newswire / December 23, 2025 / MindMaze Therapeutics Holding SA (SIX:MMTX…

3 hours ago

MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics

GENEVA, SWITZERLAND / ACCESS Newswire / December 23, 2025 / MindMaze Therapeutics Holding SA (SIX:MMTX…

3 hours ago

MindHYVE.ai™ and KPSIAJ Sign Strategic MOU to Advance AI-Driven Innovation in Education and Healthcare Across Karachi

KARACHI, Pakistan, Dec. 22, 2025 /PRNewswire/ -- MindHYVE.ai, Inc., and Khoja (Pirhai) Shia Isna Asheri Jamaat…

6 hours ago

Castle Connolly Names Dr. Meegan Gruber, MD, PhD a 2026 Exceptional Woman in Medicine; Recognition to Be Featured in New York Magazine

Board-certified plastic surgeon and surgeon-scientist honored for clinical excellence, leadership, and commitment to patient education. …

6 hours ago

Planning Time Off in 2026: Dr. Meegan Gruber, MD, PhD Releases a Recovery-Logistics Guide for Busy Professionals Considering Plastic Surgery

New "Recovery Logistics" checklist helps patients coordinate work, childcare, travel, and follow-up support-before they choose…

6 hours ago